Terms: = Bone cancer AND BCL11A, BCL11A-L, 53335, ENSG00000119866, FLJ34997, CTIP1, BCL11A-S, BCL11A-XL, KIAA1809, Q9H165, EVI9, FLJ10173 AND Treatment
4 results:
1. Hurdles to the Adoption of Gene Therapy as a Curative Option for Transfusion-Dependent Thalassemia.
Thuret I; Ruggeri A; Angelucci E; Chabannon C
Stem Cells Transl Med; 2022 Apr; 11(4):407-414. PubMed ID: 35267028
[TBL] [Abstract] [Full Text] [Related]
2. bcl11a promotes myeloid leukemogenesis by repressing PU.1 target genes.
Sunami Y; Yokoyama T; Yoshino S; Takahara T; Yamazaki Y; Harada H; Nakamura T
Blood Adv; 2022 Mar; 6(6):1827-1843. PubMed ID: 34714913
[TBL] [Abstract] [Full Text] [Related]
3. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease.
Altrock PM; Brendel C; Renella R; Orkin SH; Williams DA; Michor F
Am J Hematol; 2016 Sep; 91(9):931-7. PubMed ID: 27299299
[TBL] [Abstract] [Full Text] [Related]
4. A retroviral mutagenesis screen reveals strong cooperation between bcl11a overexpression and loss of the Nf1 tumor suppressor gene.
Yin B; Delwel R; Valk PJ; Wallace MR; Loh ML; Shannon KM; Largaespada DA
Blood; 2009 Jan; 113(5):1075-85. PubMed ID: 18948576
[TBL] [Abstract] [Full Text] [Related]
